Search ASX code:
Generic filters

Search ASX code:
Generic filters

Search ASX code:
Generic filters

Want to invest ethically for a brighter future?
(but still make lots of money)?

Want to invest ethically for a brighter future? (but still make lots of money)?

 Take Rask’s FREE Ethical Investing course today.

  • Online & 100% free
  • ETFs, shares & Super
Want to invest ethically for a brighter future? 
(but still make lots of money)?

 Take Rask’s FREE online Ethical Investing course.

Investing on the ASX? Here’s 2 growth shares I’m watching in March 2021

Here are two ASX growth stocks that I think could be sound long-term investments, to add to your watchlist today. ASX Reporting Season can bring about a lot of fluctuation in share prices for all listed companies so I think now is the time to go on the hunt for new ideas.

Volatility and news flow like this can offer investors an opportunity to invest in a high-quality business that may have suffered a temporary blip in performance. The hard part is trying to figure out whether it’s a temporary or structural change to the core businesses, which should always be at the forefront of investors’ minds.

1. Whispir Ltd (ASX: WSP)

Whispir installs applications into existing workflow solutions to automate business-critical communications across mobile, email, voice, social and the web. It essentially optimises communications between people and organisations at scale. The company went into a trading halt this week to raise capital to fund growth.

The challenges of communication between organisations and staff became prominent during the pandemic due to constant public health announcements. This resulted in a spike in demand for Whispir’s cloud-based products and services.

Despite the improvement in the COVID situation as cases decline across the globe, Whispir’s existing customers still purchased additional products. I think this reflects the importance of effective communication between organisations and people, as well as the stickiness of Whispir’s product.

Whispir’s share price has fallen since its earnings results for the half-year despite recording strong growth.

Whispir continues to gain traction in Asia, offsetting a decline in growth in the North America market. Despite the decline in North America, there are big companies using Whispir like Twilio (NYSE: TWLO), which showcases the high quality of Whispir’s product offering.

It seems Mr Market had higher expectations for growth but the focus for me is Whispir’s product. If Whispir can execute in North America, this could be a sound long-term investment.

2. Nuix Ltd (ASX: NXL)

Nuix equips organisations to process large amounts of unstructured data into a format that can assist clients to investigate, manage, secure, de-risk, and utilise it for a variety of use cases. This company only listed on the ASX in December 2020 and there was a lot of hype.

The hype resulted in Nuix being priced at 24.7x projected earnings of $63.6 million for the IPO.

However, it appears Nuix failed to meet the market’s high growth expectations as the share price continues to drop after releasing its results for the half-year. The company’s revenue declined in this period, but there appears to be a good reason for this.

The company noted more customers are switching from on-premise, perpetual software licencing to consumption-based licencing. As a result, revenue is now more spread out over time.

Even though Nuix recorded lower revenue, it still managed to secure 49 new customers and churn remained low at 4.2% for HY21. I like Nuix’s strong customer base, low customer churn and the long runway for growth in the data space. In saying that, the current price still remains a tad expensive for my liking, so I’ll keep twiddling my fingers on this one. View more ASX growth shares.

1 ASX Stock to Buy RIGHT NOW...

Rask's top analyst has just identified his #1 'MedTech' stock idea for 2021 and beyond. This is a SERIOUS growth stock.

CLICK HERE to get the ASX stock ticker code, 3,500-word analysis and ASX founder interview!

Our expert investment reports are 100% free.

Simply click here or enter your email below. We'll send you the report.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Rask's top analyst has just identified his #1 'MedTech' stock idea for 2021 and beyond. This is a SERIOUS growth stock.

CLICK HERE to get the ASX stock ticker code, 3,500-word analysis and ASX founder interview!

Our expert investment reports are 100% free.

Simply click here or the button below. We'll email you the report.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Keep reading: